Standout Papers

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure... 1999 2026 2008 2017 6.2k
  1. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure (1999)
    Bertram Pitt, Faı̈ez Zannad et al. New England Journal of Medicine
  2. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure (2000)
    Bertram Pitt, Faı̈ez Zannad et al. Survey of Anesthesiology
  3. The Seattle Heart Failure Model (2006)
    Wayne C. Levy, Dariush Mozaffarian et al. Circulation
  4. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (2020)
    George L. Bakris, Rajiv Agarwal et al. New England Journal of Medicine
  5. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II (2000)
    Bertram Pitt, Philip A. Poole‐Wilson et al. The Lancet
  6. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction (1996)
    Albert L. Waldo, A. John Camm et al. The Lancet
  7. Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease (1996)
    G.B. John Mancini, Carlos Macaya et al. Circulation
  8. Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure (2000)
    Faı̈ez Zannad, François Alla et al. Circulation
  9. A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction (1987)
    Eric J. Topol, Robert M. Califf et al. New England Journal of Medicine
  10. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2021)
    Rajiv Agarwal, Gerasimos Filippatos et al. European Heart Journal
  11. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors (2014)
    Matthew R. Weir, George L. Bakris et al. New England Journal of Medicine
  12. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial (2013)
    Bertram Pitt, Lars Køber et al. European Heart Journal
  13. Sudden death in the year following myocardial infarction (1977)
    H. William Strausś, Bertram Pitt et al. The American Journal of Medicine
  14. Thallium-201 myocardial perfusion imaging at rest and during exercise. Comparative sensitivity to electrocardiography in coronary artery disease. (1977)
    I. K. Bailey, Lawrence S.C. Griffith et al. Circulation
  15. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction (2014)
    Robert J. Mentz, Jacob P. Kelly et al. Journal of the American College of Cardiology
  16. Thallium-201 for myocardial imaging. Relation of thallium-201 to regional myocardial perfusion. (1975)
    H. William Strausś, James Langan et al. Circulation
  17. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction (2015)
    Scott D. Solomon, Brian Claggett et al. European Heart Journal
  18. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone (2015)
    Amil M. Shah, Brian Claggett et al. Circulation
  19. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease (2015)
    George L. Bakris, Bertram Pitt et al. JAMA
  20. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease (2016)
    Gerasimos Filippatos, Stefan D. Anker et al. European Heart Journal
  21. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes (2017)
    Allan J. Collins, Bertram Pitt et al. American Journal of Nephrology
  22. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis (2024)
    Pardeep S. Jhund, Atefeh Talebi et al. The Lancet

Immediate Impact

127 standout
Sub-graph 1 of 17

Citing Papers

Empagliflozin in Patients with Chronic Kidney Disease
2022 Standout
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
2020 Standout
2 intermediate papers

Works of Bertram Pitt being referenced

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
Clinical consequences of angiotensin-converting enzyme inhibitor withdrawl in chronic heart failure: A double-blind, placebo-controlled study of quinapril
1993
and 2 more

Author Peers

Author Last Decade Papers Cites
Bertram Pitt 31804 11643 8449 8885 574 44.5k
Aldo P. Maggioni 34479 9166 5216 7671 859 47.2k
Lars Køber 38013 9752 5442 10184 1.3k 57.2k
Milton Packer 51532 10135 8320 9120 646 63.5k
Karl Swedberg 51899 9433 8567 5758 504 62.2k
Javed Butler 27960 7642 5970 6190 807 40.0k
Gerasimos Filippatos 29741 7580 7290 6070 611 41.9k
Faı̈ez Zannad 37457 18639 11331 9964 946 55.6k
Michael Böhm 38042 7294 6189 14032 1.1k 61.0k
Dirk J. van Veldhuisen 42486 5454 7531 7636 852 58.8k
Christopher B. Granger 48225 4003 4722 13453 833 62.0k

All Works

Loading papers...

Rankless by CCL
2026